Nektar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 137
- Market Cap
- $230M
- Website
- http://www.nektar.com
- Introduction
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cance...
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 84
- Registration Number
- NCT06340360
- Locations
- 🇨🇦
Nektar Investigative Site, Sherbrooke, Quebec, Canada
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 396
- Registration Number
- NCT06136741
- Locations
- 🇪🇸
Nektar Investigative Site, Zaragoza, Spain
🇭🇷Nektar Investigative Site 5701, Zagreb, Grad Zagreb, Croatia
🇭🇷Nektar Investigative Site 5703, Zagreb, Grad Zagreb, Croatia
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 400
- Registration Number
- NCT05664217
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
A Phase I Study of LY3471851 in Healthy Participants
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT05565729
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
A Single-Dose Study of LY3471851 in Healthy Participants
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT04998487
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT04969861
- Locations
- 🇦🇹
Universitätsklinikum Salzburg, Landeskrankenhaus,, Salzburg, Salzburg Bundesland, Austria
🇬🇷Attikon University General Hospital, Athens, Attiki, Greece
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Nektar Therapeutics
- Registration Number
- NCT04955262
- Locations
- 🇺🇸
Investigational Site - Duarte, Duarte, California, United States
🇺🇸Investigational Site - Portland, Portland, Oregon, United States
🇺🇸Investigational Site - Philadelphia, Philadelphia, Pennsylvania, United States
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 81
- Registration Number
- NCT04677179
- Locations
- 🇺🇸
Care Access Research - Ogden, Ogden, Utah, United States
🇦🇺St. Vincent's Hospital, Fitzroy, Victoria, Australia
🇨🇦CISSS de la Montérégie - Centre Hôpital Charles-Le Moyne, Greenfield Park, Quebec, Canada
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04646044
- Locations
- 🇺🇸
SMS Clinical Research, LLC, Mesquite, Texas, United States
🇺🇸Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park, Florida, United States
🇺🇸A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT04616196
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸START Center for Cancer Care, San Antonio, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States